信达证券发布上海医药研报，24H1商业业务逆势增长，新药&中药有望带来第二增长动力

七印授权

3TQ9493XGYLOJTLLWW35LHG230U3LENNKOH9TI1D8HJI6HBRK2

2024-08-29 15:07:35

article

516F2E4DFDB049AE09910BF7B532DD2CC3A0AF50F35DAFC8EA359A1C9C227B37

zh-CN

F1722BF5545DAA771A01AACBAB2DE8BF946DC900

17032654

02636d79fc7c7cc37b9cb348037eec28743d030e5d570d0d69837a3587bed31880

3da6383d2b451d9d0fa20967e6d0bb9bfacb8b07cfac3c6184be1f7ebe553e7d66ad12e60203b311addd618be5d518fe02a1598eaa8bc0b523ab138bf46bab7c1c

{"parameters":{"adaptation":"n","price":"100000"},"type":"cm"}

yuanben_66d08eb7c384e6.21947765

原本认证

https://www.yuanben.io/article/83b2c062-28ff-475a-bf04-5fc042eab976

{"author":"每日经济新闻","authorization_pub_key":"03040cbbeae1adf91c3efd7306d09c6005403a041f9b7405dac489d4f8126fef8c"}